Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The effects of adding quinolones to beta-lactam antibiotics for sepsis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Does rocking motion calm delirious patients in ICU? A multicentre randomised clinical trial protocol (RockingICU)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Iatrogenic withdrawal syndrome frequently occurs in paediatric intensive care without algorithm for tapering of analgosedation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Is clinical heterogeneity the foremost prominent threat to the validity of meta-analyses?

    Research output: Contribution to journalEditorialResearchpeer-review

  5. Meta-analyses of gabapentinoids for pain management after knee arthroplasty - a caveat emptor? A narrative review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: In the early phase of the pandemic, some guidelines recommended the use of corticosteroids for critically ill patients with COVID-19, whereas others recommended against the use despite lack of firm evidence of either benefit or harm. In the COVID STEROID trial, we aimed to assess the effects of low-dose hydrocortisone on patient-centred outcomes in adults with COVID-19 and severe hypoxia.

METHODS: In this multicentre, parallel-group, placebo-controlled, blinded, centrally randomised, stratified clinical trial, we randomly assigned adults with confirmed COVID-19 and severe hypoxia (use of mechanical ventilation or supplementary oxygen with a flow of at least 10 L/min) to either hydrocortisone (200 mg/d) vs a matching placebo for 7 days or until hospital discharge. The primary outcome was the number of days alive without life support at day 28 after randomisation.

RESULTS: The trial was terminated early when 30 out of 1000 participants had been enrolled because of external evidence indicating benefit from corticosteroids in severe COVID-19. At day 28, the median number of days alive without life support in the hydrocortisone vs placebo group were 7 vs 10 (adjusted mean difference: -1.1 days, 95% CI -9.5 to 7.3, P = .79); mortality was 6/16 vs 2/14; and the number of serious adverse reactions 1/16 vs 0/14.

CONCLUSIONS: In this trial of adults with COVID-19 and severe hypoxia, we were unable to provide precise estimates of the benefits and harms of hydrocortisone as compared with placebo as only 3% of the planned sample size were enrolled.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT04348305. European Union Drug Regulation Authorities Clinical Trials (EudraCT) Database: 2020-001395-15.

Original languageEnglish
JournalActa Anaesthesiologica Scandinavica
ISSN0001-5172
DOIs
Publication statusE-pub ahead of print - 17 Jun 2021

ID: 66420211